CD274 and head and neck squamous cell carcinoma: Buparlisib in combination with paclitaxel compared to paclitaxel alone is currently being assessed in the phase 3 BURAN trial for R/M HNSCC that have progressed after prior platinum-based therapy with or without prior anti-PD1/anti-PDL1 therapy (NCT04338399).